article thumbnail

Lundbeck planning for four novel drugs in phase 3 in 2026

pharmaphorum

Denmark's Lundbeck has said that efforts to build its R&D portfolio are on track to deliver four new molecular entities (NMEs) in phase 3 trials in 2026, including an epilepsy drug from its recently announced $2.6 billion takeover of Longboard Pharma.

104
104
article thumbnail

Concerns prescribing service will not be ready by 2026

The Pharmacist

Slow progress on the community pharmacy prescribing pathfinder project has sparked concerns that a viable commissioned community pharmacy prescribing service will not be ready by 2026, The Pharmacist has learned.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapy

Pharmaceutical Technology

Regenxbio’s plans toward a BLA filing in 2026 after positive data from the Phase I/II AFINITY DUCHENNE trial.

52
article thumbnail

Pandemic vaccination regulations extended to 2026

The Pharmacist

Vaccination regulations adopted due to the Covid pandemic will be extended until 2026 following a Government consultation. Ministers will extend the regulations until 1 April 2026 to support the supply, distribution and administration of Covid and flu vaccines as the country transitions out of the pandemic.

article thumbnail

Dr R. N. gupta elected National President of Indian Pharmaceutical Association for 2024-2026 term

Express Pharma

Gupta has been elected as the National President of the Indian Pharmaceutical Association (IPA) for the term 2024-2026. Dr Gupta’s term will run from October 1, 2024 to 30th September 2026. gupta elected National President of Indian Pharmaceutical Association for 2024-2026 term appeared first on Express Pharma. The post Dr R.

article thumbnail

AI to revolutionise drug development by 2026

European Pharmaceutical Review

Over 50 percent of respondents answered that machine learning for optimisation of manufacturing processes will be the technology that will be used routinely in the pharmaceutical industry by 2026. The post AI to revolutionise drug development by 2026 appeared first on European Pharmaceutical Review.

article thumbnail

GS Krishnan re-elected ABLE President for 2024 -2026

Express Pharma

GS Krishnan, President of Association of Biotechnology Led Enterprises (ABLE) has been re-elected for another two-year term from April 2024 – 2026. The post GS Krishnan re-elected ABLE President for 2024 -2026 appeared first on Express Pharma.

104
104